Abstract:P53 is well recognized to be a tumor suppressor protein. In response to the external stress or environmental perturbation, p53 can promote the transcription of various target genes downstream, thus regulating the cell cycle, apoptosis, DNA repair, and angiogenesis. However, the activation of p53 is further activated by another protein, MDM2, which negatively regulates the level of p53 inverse and thus reduces the activation of p53. This phenomenon is a novel potential and promising strategy for cancer therapy, i.e. restoring the activity of p53 pathway through the competitive inhibitors that can occupy the p53-binding site of MDM2 and thus inhibit the interaction between p53 and MDM2.Recently, various kinds of the inhibitors have been designed for this purpose. The Nutlin family is a group of well investigated inhibitors, which shows high efficiency for tumor suppression. Nutlin-3a mimics the MDM2-binding site of p53 essentially, and blocks the binding of MDM2 to p53. Once getting free from MDM2, p53 rapidly accumulates in the nuclei of cancer cells, the p53 target genes and the p53 pathway are activated, thereby resulting in cell-cycle arrest and apoptosis. In our previous papers, we investigated the competition mechanism between Nutlin3 and p53 in vitro by using molecular dynamics simulations. We found that Nutlin3 can bind faster than p53 to prevent p53 from binding to MDM2 when Nutlin-3a and p53 have equal distance from MDM2. Nutlin-3a can also bind to the p53-MDM2 complex to disturb and weaken the interactions between p53 and MDM2. However, the underlying mechanisms of p53-MDM2 complex instability in vivo are still unclear. And these inhibitors also have a variety of specificities and biological toxicities in vivo environment.In this study, we go a further step to investigate the effect of Nutlin-3a on the stability of p53-MDM2 complex in physiological environment with the aid of the molecular mechanics/generalized borne surface area (MM/GBSA) method. In our simulations, a group of Nutlin-3a molecules are randomly put around the p53 binding pocket of MDM2 in the initial stages to examine the dynamics among p53, MDM2 and the group of Nutlin-3a molecules and to analyze the underlying competition mechanism between Nutlin3 and p53 binding to pocket of MDM2.We find that Nutlin-3a can induce the centroid distance between p53 and MDM2 to increase. Importantly, we show that Nutlin-3a weakens the binding affinity of p53-MDM2 complex. Consistently, Nutlin-3a breaks a hydrogen bond between Phe19-Gln72 and a salt bridge between Glu17-Lys94, which weakens the interactions between p53 and MDM2. From the systematic biology point of view, the regulation of p53 by MDM2 is extremely sensitive to the strength of the p53-MDM2 interaction. The avianization of the interactions between p53 and MDM2 by Nutlin-3a can promote p53 to restore its suppression functions on tumor development.This study may be helpful in understanding the molecular mechanisms of p53-MDM2 complex instability mediated by Nutlin-3a and also in searching for the effective inhibitors of p53-MDM2 interaction.

Nutlin-3 suppresses tumorigenesis and progression of oral squamous cell carcinoma and enhances chemosensitivity to cisplatin

Nutlin-3 Reverses the Epithelial-Mesenchymal Transition in Gemcitabine-Resistant Hepatocellular Carcinoma Cells.

Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation

Nutlin-3-induced Sensitization of Non-Small Cell Lung Cancer Stem Cells to Axitinib-Induced Apoptosis through Repression of Akt1/Wnt Signaling.

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.

Modeling the Etiology of p53-mutated Cancer Cells

RNA N6-Methyladenosine (m6A) Methyltransferase-Like 3 Facilitates Tumorigenesis and Cisplatin Resistance of Arecoline-Exposed Oral Carcinoma

Persistent P21 Expression after Nutlin-3a Removal is Associated with Senescence-Like Arrest in 4n Cells

Nutlin-3 Inhibits Epithelial–mesenchymal Transition by Interfering with Canonical Transforming Growth Factor-Β1-smad-snail/slug Axis

Nutlin-3 Overcomes Arsenic Trioxide Resistance and Tumor Metastasis Mediated by Mutant P53 in Hepatocellular Carcinoma

MDM2 Antagonist Can Inhibit Tumor Growth in Hepatocellular Carcinoma with Different Types of P53 in Vitro.

Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma

Abstract 1536: Characterization of tumor cell lines selected for resistance to the HDM2 antagonist Nutlin-3a

Effect of Nutlin-3a on Stability of P53-Mdm2 Complex

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

Vitamin D Promotes the Cisplatin Sensitivity of Oral Squamous Cell Carcinoma by Inhibiting LCN2-modulated NF-κB Pathway Activation Through RPS3.

CCN5 inhibits proliferation and promotes apoptosis of oral squamous cell carcinoma cells

Disruption of P73-Mdm2 Binding Synergizes with Gemcitabine to Induce Apoptosis in Hucct1 Cholangiocarcinoma Cell Line with P53 Mutation

Fe-SOD Cooperates with Nutlin3 to Selectively Inhibit Cancer Cells in Vitro and in Vivo

SP2-induced Circpum1 Modulates Chemoresistance and Nature Killer Cell Toxicity in Oral Squamous Cell Carcinoma

MiR-222 Targeted PUMA to Improve Sensitization of UM1 Cells to Cisplatin